Kidney Cancer Special Issue 2022

Discovering different genetic mutations to target ... continues to add to the excitement.

Going through cancer is a marathon, not a sprint.

As a part of its “Speaking Out” video series, CURE® spoke with Meryl Uranga, on behalf of KidneyCAN, about the importance of working as a team with their clinicians and getting educated before making decisions.

One expert explains how the road to cancer drug development isn’t a smooth one, but progress can be made nonetheless.

FDA-approved immunotherapies offer patients with metastatic or recurrent sarcomatoid RCC more treatment choices and improved outcomes.

HIF-2 alpha inhibitors are transforming therapy for patients with renal cell carcinoma and von Hippel-Lindau disease.

Newer drugs for kidney cancer have proven extremely effective but can cause unwanted symptoms that affect safety and quality of life.